Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis is the most common type of
small blood vessel inflammation in adults. ANCA-associated vasculitis includes Wegener's
granulomatosis (WG) and microscopic polyangiitis (MPA). Rituximab is a man-made antibody used
to treat certain types of cancer. The purpose of this study is to determine the effectiveness
of rituximab in treating patients with WG and MPA.
Study hypothesis: Rituximab is not inferior to conventional therapy in its ability to induce
disease remission by Month 6.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)